Search results

1. ESMO 2024 – Bristol bucks the degrader trend

   ESMO 2024 – Bristol bucks the degrader trend …

   
    

   Jacob Plieth
    
   - 09/17/2024 - 12:26

2. ESMO 2024 – Astellas defends its degrader

   ESMO 2024 – Astellas defends its degrader …

   
    

   Madeleine Armstrong
    
   - 10/09/2024 - 14:56

3. ESMO 2024 – Scorpion joins Relay in the alpha club

   ESMO 2024 – Scorpion joins Relay in the alpha club …

   
    

   Jacob Plieth
    
   - 09/18/2024 - 21:45

4. ESMO 2024 – J&J eyes Rybrevant colorectal expansion

   ESMO 2024 – J&J eyes Rybrevant colorectal expansion …

   
    

   Madeleine Armstrong
    
   - 09/16/2024 - 12:28

5. ESMO 2024 – a role for immunotherapy in ovarian cancer

   ESMO 2024 – a role for immunotherapy in ovarian cancer …

   
    

   Jacob Plieth
    
   - 09/15/2024 - 21:18

6. ESMO 2024 – combos could be the way forward for CDK2

   ESMO 2024 – combos could be the way forward for CDK2 … Pfizer Blueprint Medicines Presentation ESMO 2024 ESMO 2024 ASCO 2023 ASCO 2024 Study Ph1 …

   
    

   Madeleine Armstrong
    
   - 09/15/2024 - 21:18

7. ESMO 2024 – Keytruda/Lenvima leap... up to a point

   ESMO 2024 – Keytruda/Lenvima leap... up to a point …

   
    

   Jacob Plieth
    
   - 09/15/2024 - 15:51

8. ESMO 2024 – Opdualag comes under fire

   ESMO 2024 – Opdualag comes under fire …

   
    

   Jacob Plieth
    
   - 09/15/2024 - 08:35

9. ESMO 2024 – Astra’s B7-H4 effort underwhelms

   ESMO 2024 – Astra’s B7-H4 effort underwhelms … inhibitor 8 Ph1/2 in solid tumours ESMO 2024: ORR 20% (9/44 PRs) in ≥1.6mg/kg; incl 25% (3/12 …

   
    

   Madeleine Armstrong
    
   - 09/15/2024 - 08:35

10. ESMO 2024 – iTeos TIGIT meets its efficacy criteria

    ESMO 2024 – iTeos TIGIT meets its efficacy criteria …

    
     

    Jacob Plieth
     
    - 09/15/2024 - 08:34